All In MedTech

FDA Clearance Tracker · P940035

NMP22 BladderChek Test

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 21, 2026Latest source record: Jul 2, 1996 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

The decision

FDA number
P940035
Device name
NMP22 BladderChek Test
Applicant location
Scarborough, ME
Received
Nov 7, 1994
Decided
Jul 2, 1996
Decision
Approved
Supplements
17 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NAH

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MATRITECH NMP22 TEST KIT. THE MATRITECH NMP22 TEST KIT IS AN ENZYME IMMUNOASSAY (EIA) FOR THE IN VITRO QUANTITATIVE DETERMINATION OF NUCLEAR MATRIX PROTEIN NMP22 IN STABILIZED VOIDED URINE.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NAH (System, test, tumor marker, for detection of bladder cancer).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Diagnostics Scarborough, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.